Literature DB >> 25245804

Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.

Ravinder Kaur1, Naveen Surendran1, Martina Ochs2, Michael E Pichichero3.   

Abstract

Streptococcus pneumoniae adherence to human epithelial cells (HECs) is the first step in pathogenesis leading to infections. We sought to determine the role of human antibodies against S. pneumoniae protein vaccine candidates PhtD, PcpA, and Ply in preventing adherence to lung HECs in vitro and mouse nasopharyngeal (NP) colonization in vivo. Human anti-PhtD, -PcpA, and -Ply antibodies were purified and Fab fragments generated. Fabs were used to test inhibition of adherence of TIGR4 and nonencapsulated strain RX1 to A549 lung HECs. The roles of individual proteins in adherence were tested using isogenic mutants of strain TIGR4. Anti-PhtD, -PcpA, and -Ply human antibodies were assessed for their ability to inhibit NP colonization in vivo by passive transfer of human antibody in a murine model. Human antibodies generated against PhtD and PcpA caused a decrease in adherence to A549 cells (P < 0.05). Anti-PhtD but not anti-PcpA antibodies showed a protective role against mouse NP colonization. To our surprise, anti-Ply antibodies also caused a significant (P < 0.05) reduction in S. pneumoniae colonization. Our results support the potential of PhtD, PcpA, and Ply protein vaccine candidates as alternatives to conjugate vaccines to prevent non-serotype-specific S. pneumoniae colonization and invasive infection.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245804      PMCID: PMC4249272          DOI: 10.1128/IAI.02124-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin.

Authors:  P Balachandran; S K Hollingshead; J C Paton; D E Briles
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

2.  Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies.

Authors:  Sandra Romero-Steiner; Tamar Pilishvili; Jacquelyn S Sampson; Scott E Johnson; Annie Stinson; George M Carlone; Edwin W Ades
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

3.  Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence.

Authors:  Jason W Johnston; David E Briles; Lisa E Myers; Susan K Hollingshead
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  J N Weiser; Z Markiewicz; E I Tuomanen; J H Wani
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Authors:  Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Philippe Denoël; Jan T Poolman
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

7.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants.

Authors:  Jacinta P Francis; Peter C Richmond; William S Pomat; Audrey Michael; Helen Keno; Suparat Phuanukoonnon; Jan B Nelson; Melissa Whinnen; Tatjana Heinrich; Wendy-Anne Smith; Susan L Prescott; Patrick G Holt; Peter M Siba; Deborah Lehmann; Anita H J van den Biggelaar
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 9.  Otitis media.

Authors:  Michael E Pichichero
Journal:  Pediatr Clin North Am       Date:  2013-04       Impact factor: 3.278

10.  PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans.

Authors:  M Nadeem Khan; Sharad K Sharma; Laura M Filkins; Michael E Pichichero
Journal:  Microbes Infect       Date:  2012-07-14       Impact factor: 2.700

View more
  12 in total

Review 1.  Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.

Authors:  Jennifer A Grousd; Helen E Rich; John F Alcorn
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

2.  Comparison of specific in-vitro virulence gene expression and innate host response in locally invasive vs colonizer strains of Streptococcus pneumoniae.

Authors:  Naoko Fuji; Michael E Pichichero; Ravinder Kaur
Journal:  Med Microbiol Immunol       Date:  2021-03-22       Impact factor: 3.402

Review 3.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

Review 4.  Rationale and prospects for novel pneumococcal vaccines.

Authors:  Kristin Moffitt; Richard Malley
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 5.  Next generation protein based Streptococcus pneumoniae vaccines.

Authors:  Michael E Pichichero; M Nadeem Khan; Qingfu Xu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.

Authors:  Martina M Ochs; Kimberley Williams; Anthony Sheung; Philippe Lheritier; Lucian Visan; Nicolas Rouleau; Emilie Proust; Aymeric de Montfort; Mei Tang; Karine Mari; Robert Hopfer; Scott Gallichan; Roger H Brookes
Journal:  Hum Vaccin Immunother       Date:  2016-11       Impact factor: 3.452

7.  Insights into structure and activity of natural compound inhibitors of pneumolysin.

Authors:  Hongen Li; Xiaoran Zhao; Xuming Deng; Jianfeng Wang; Meng Song; Xiaodi Niu; Liping Peng
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

8.  Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

Authors:  Els van Westen; Martien C M Poelen; Germie P J M van den Dobbelsteen; Eliud O Oloo; Martina M Ochs; Nynke Y Rots; Cecile A C M van Els
Journal:  PLoS One       Date:  2018-03-06       Impact factor: 3.240

9.  Epigallocatechin gallate inhibits Streptococcus pneumoniae virulence by simultaneously targeting pneumolysin and sortase A.

Authors:  Meng Song; Zihao Teng; Meng Li; Xiaodi Niu; Jianfeng Wang; Xuming Deng
Journal:  J Cell Mol Med       Date:  2017-04-12       Impact factor: 5.310

Review 10.  Pneumolysin: Pathogenesis and Therapeutic Target.

Authors:  Andrew T Nishimoto; Jason W Rosch; Elaine I Tuomanen
Journal:  Front Microbiol       Date:  2020-07-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.